DK1447414T3 - Antagonistpeptider af carcinoembronisk antigen (CEA) - Google Patents

Antagonistpeptider af carcinoembronisk antigen (CEA)

Info

Publication number
DK1447414T3
DK1447414T3 DK04011673T DK04011673T DK1447414T3 DK 1447414 T3 DK1447414 T3 DK 1447414T3 DK 04011673 T DK04011673 T DK 04011673T DK 04011673 T DK04011673 T DK 04011673T DK 1447414 T3 DK1447414 T3 DK 1447414T3
Authority
DK
Denmark
Prior art keywords
cea
peptides
carcinoembryonic antigen
antigen antagonist
agonists
Prior art date
Application number
DK04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1447414T3 publication Critical patent/DK1447414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04011673T 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA) DK1447414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
DK1447414T3 true DK1447414T3 (da) 2007-09-10

Family

ID=22036775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04011673T DK1447414T3 (da) 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA)

Country Status (11)

Country Link
EP (1) EP1017810B1 (da)
JP (1) JP4291508B2 (da)
AT (2) ATE364048T1 (da)
AU (1) AU745863B2 (da)
CA (1) CA2308127C (da)
CY (1) CY1107706T1 (da)
DE (2) DE69837896T2 (da)
DK (1) DK1447414T3 (da)
ES (2) ES2217585T3 (da)
PT (1) PT1447414E (da)
WO (1) WO1999019478A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
CA2416893A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
EP2301356A3 (en) * 2002-12-04 2012-05-30 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016112188A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
DE69824023T2 (de) 2005-05-12
CA2308127C (en) 2011-03-22
AU745863B2 (en) 2002-04-11
JP2002500002A (ja) 2002-01-08
ATE364048T1 (de) 2007-06-15
WO1999019478A1 (en) 1999-04-22
ES2286530T3 (es) 2007-12-01
EP1017810A1 (en) 2000-07-12
ES2217585T3 (es) 2004-11-01
ATE267213T1 (de) 2004-06-15
CY1107706T1 (el) 2013-04-18
EP1017810B1 (en) 2004-05-19
JP4291508B2 (ja) 2009-07-08
DE69837896D1 (de) 2007-07-19
PT1447414E (pt) 2007-07-18
AU9500498A (en) 1999-05-03
DE69837896T2 (de) 2008-02-14
DE69824023D1 (de) 2004-06-24
CA2308127A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ATE272070T1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69942072D1 (de) Von der Telomerase abgeleitete antigene Peptide
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
DE69533923D1 (de) Cytokinin-designiertes lerk-5
GEP20074091B (en) Cripto blocking antibodies and uses thereof
PT1066380E (pt) Receptor de celula t soluvel
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
HUP0004639A2 (hu) Chlamydia fehérje, génszekvencia és ezek alkalmazása
MY109957A (en) Improved antibodies to plasmodium falciparum
ATE346869T1 (de) Agonistische antikörper gegen tie2
GEP20105118B (en) Anti-vegf antibodies
CR8231A (es) Anticuerpos rg1 y uso de los mismos
TR200000654T2 (tr) KAY-Yeni bir bağışıklık sistemi proteini.
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP0739350A4 (en) LIGAND FIXING FAS ANTIGEN
IL145689A0 (en) Methods
TW272197B (da)
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
EP1447414A3 (en) Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva